INMB

Conviction 88HealthcareScan · Mon, Aug 10, 2026

INMB$2.13+1.92%

ResistanceSupportVol 14

Vol MA14 397.31K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Inmune Bio, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.inmunebio.com ↗

Price2.13

Change+1.92%

Gap+0.24%

Rel volume3.08×

Avg volume496.69K

Avg $ vol978.39K

SMA 201.88

SMA 501.63

SMA 2001.55

Price vs 50+30.01%

Price vs 200+37.43%

MA stackbullish

50/200 cross—

Supertrendup · 1.70

RSI (14)68

MACD hist0.02

MACD crossbull · 1d

Stoch %K / %D89 / 83

ADX (14)21

+DI / −DI28 / 13

RSI divergence—

MACD divergence—

ATR %+6.67%

ADR %7.59%

52w high2.56

52w low1.12

From 52w high-16.99%

Above 52w low+89.73%

New 52w highNo

SqueezeOff

Bollinger width31.13%

%B0.92

Donchian pos88.79%

Donchian high2.19

Donchian low1.61

AVWAP (52w high)1.69

vs AVWAP high+26.11%

AVWAP (52w low)1.59

vs AVWAP low+34.06%

OBV trendUp

Chaikin MF (20)0.13

Today vs 20d3.08×

Avg vol (14d)397.31K

Avg vol (20d)496.69K

Avg $ vol (20d)978.39K

Market cap—

RS 3m (vs SPY)+40.11%

RS 6m (vs SPY)+32.72%

RS line new highNo

Trend template5/8

Technical rank91.4

1 week+14.86%

1 month+9.54%

3 months+48.60%

6 months+40.73%

1 year-23.84%

YTD+37.99%

P/E-1.26

P/B2.85

P/S—

P/FCF-2.46

EPS-1.86

Div yield—

ROE-225.58%

ROA-171.10%

Debt/Eq0.60

Current4.04

EV/EBITDA—

Gross margin—

Net margin—

Rev growth257.14%

EPS growth-9.15%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value45.45M

Revenue50K

Net income-1.27M

Gross profit—

Free cash flow-23.62M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out26.59M

Employees21

ListedMon, Feb 4, 2019

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA+

Conviction88 / 100

Pattern quality—

Tech rank91.4 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.01

Support1.42

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in INMB

All disclosures →

No recent disclosed trades by Congress in INMB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in INMB · 3 buys · 3 sells

Insider	Side	Shares	Value	Traded	Filed
Moss David J Chief Executive Officer · Common Stock · 2026-07-02	Exercise	9.01K	$13K	2026-07-02	2026-07-07
Moss David J Chief Executive Officer · Common Stock Purchase Warrant · 2026-07-02	Exercise	9.01K	$1K	2026-07-02	2026-07-07
Juda Scott Director · Common Stock · 2026-07-02	Exercise	14.8K	$21K	2026-07-02	2026-07-07
Juda Scott Director · Common Stock Purchase Warrant · 2026-07-02	Exercise	14.8K	$2K	2026-07-02	2026-07-07
Lowdell Mark William Chief Scientific Officer · Common Stock · 2026-07-02	Exercise	7.21K	$10K	2026-07-02	2026-07-07
Lowdell Mark William Chief Scientific Officer · Common Stock Purchase Warrant · 2026-07-02	Exercise	7.21K	$901	2026-07-02	2026-07-07

SEC filings

EDGAR filings in INMB · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.